Past mCRC Leronlimab doubled the mOS @ 16 months...
FOLFOX past study:
The study included patients with stage III colon cancer treated at the 5 regional cancer centers of the British Columbia Cancer Agency.
The researchers retrospectively reviewed the charts of 475 patients who received adjuvant FOLFOX. Their median age was 62 years, and 55% were male.
The study sought to identify the key side effects associated with adjuvant FOLFOX in early colon cancer, and to look for their associations with clinical and patient-related factors.
The study included patients with stage III colon cancer treated at the 5 regional cancer centers of the British Columbia Cancer Agency.
The researchers retrospectively reviewed the charts of 475 patients who received adjuvant FOLFOX. Their median age was 62 years, and 55% were male.
Renal, Cardiovascular, and Sensory Toxicities Were Common
The most common toxicities were abnormal kidney function (61.7%), neuropathy (54.9%), and cardiovascular-related side effects (hypertension, hypotension, thromboembolism, cardiac arrest; 51.4%). Gastrointestinal (GI) toxicities, including nausea, vomiting, and diarrhea, were recorded in 44% of patients.
Other common toxicities included anemia (76%), abnormal liver enzymes (61.7%), thrombocytopenia (28%), and neutropenia (27.8%).
In a multivariate analysis, renal dysfunction (glomerular filtration rate [GFR] <50) carried a 69% increased risk of any GI toxicity.
The risk of significant neutropenia was increased 2- to 3-fold among patients whose time between diagnosis and receipt of adjuvant chemotherapy exceeded 8 weeks; those with poor performance status; those older than 70 years; and patients with low white blood cell count (<6.4 x 109).
Interestingly, multiple toxicities were more prevalent among patients who waited more than 8 weeks to initiate adjuvant FOLFOX, Gresham added.
____
Leronlimab for another easy win due to a proven historical, non-toxic profile for physcian choice
FOLFOX past study:
The study included patients with stage III colon cancer treated at the 5 regional cancer centers of the British Columbia Cancer Agency.
The researchers retrospectively reviewed the charts of 475 patients who received adjuvant FOLFOX. Their median age was 62 years, and 55% were male.
The study sought to identify the key side effects associated with adjuvant FOLFOX in early colon cancer, and to look for their associations with clinical and patient-related factors.
The study included patients with stage III colon cancer treated at the 5 regional cancer centers of the British Columbia Cancer Agency.
The researchers retrospectively reviewed the charts of 475 patients who received adjuvant FOLFOX. Their median age was 62 years, and 55% were male.
Renal, Cardiovascular, and Sensory Toxicities Were Common
The most common toxicities were abnormal kidney function (61.7%), neuropathy (54.9%), and cardiovascular-related side effects (hypertension, hypotension, thromboembolism, cardiac arrest; 51.4%). Gastrointestinal (GI) toxicities, including nausea, vomiting, and diarrhea, were recorded in 44% of patients.
Other common toxicities included anemia (76%), abnormal liver enzymes (61.7%), thrombocytopenia (28%), and neutropenia (27.8%).
In a multivariate analysis, renal dysfunction (glomerular filtration rate [GFR] <50) carried a 69% increased risk of any GI toxicity.
The risk of significant neutropenia was increased 2- to 3-fold among patients whose time between diagnosis and receipt of adjuvant chemotherapy exceeded 8 weeks; those with poor performance status; those older than 70 years; and patients with low white blood cell count (<6.4 x 109).
Interestingly, multiple toxicities were more prevalent among patients who waited more than 8 weeks to initiate adjuvant FOLFOX, Gresham added.
____
Leronlimab for another easy win due to a proven historical, non-toxic profile for physcian choice
8
